Scarica l'app Stockscreener
3.66
6.15%
-0.24
Dopo l'orario di chiusura:
3.75
0.09
+2.46%
Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie
Jefferies raises SAB Biotherapeutics price target on FDA approval By Investing.com - Investing.com Canada
SABS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10.00 - GuruFocus
SABSW Warrants Trade Near Par Value as SAB Biotherapeutics Warrants Hold SteadySell Signal Alerts - newsline.com
SABS Q1 2026 Earnings: EPS Misses Estimates Amid Operational DevelopmentsCFO Commentary Report - newsline.com
SAB Biotherapeutics, Inc. (SABS) Presents at FOCIS 2026 Annual MeetingSlideshow (NASDAQ:SABS) 2026-06-10 - Seeking Alpha
SAB Biotherapeutics (SABS) Edges Lower, Holds Above Key Support Amid Biotechnology Sector CautionSmall Cap Breakouts - newsline.com
Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Deliver On Growth Plans? - Sahm
SABS Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineLow Estimate Range - newsline.com
SABS Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - newsline.com
SABS - Finviz
SAB Biotherapeutics to Present Data on SAB-142 for Type 1 Diabetes at Upcoming ADA and FOCIS Congresses - Quiver Quantitative
Potential T1D immunotherapy SAB-142 to feature at two June medical meetings - Stock Titan
SABS Technical Analysis & Stock Price Forecast - Intellectia AI
SAB Biotherapeutics (SABS) Slides 3.81% as Biotech Sector Faces Headwinds; Key Support TestedStock Surge Alerts - The Legal Advocate
SABS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Citi Initiates SAB Biotherapeutics(SABS.US) With Buy Rating, Announces Target Price $11 - Moomoo
Citigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SABS Q1 2026 Earnings: Wider-than-Expected Loss as Biotech Continues Development; Shares Edge HigherFinancial Health Score - Newser
Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target - marketscreener.com
Jefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SABS Initiated Coverage by Jefferies -- Rating Set to Buy - GuruFocus
Jefferies Initiates SAB Biotherapeutics at Buy With $11 Price Target - Moomoo
Jefferies initiates SAB Biotherapeutics stock with buy on diabetes therapy potential - Investing.com Australia
SAB Biotherapeutics Q1 earnings call highlights - MSN
Why Is SAB Biotherapeutics, Inc. (SABSW) Stock Up Today? - Meyka
SAB Biotherapeutics (SABS) Q1 2026 Miss: What Went WrongCore Business Growth - Newser
Number of shareholders of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
Certain Restricted Stock Grants of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026. - marketscreener.com
Certain Warrants of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026. - marketscreener.com
47,609,899 Common Stock of SAB Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-MAY-2026. - marketscreener.com
Guggenheim Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Perceptive Advisors (SABS) discloses 8.4% ownership — 6.43M shares - Stock Titan
Caligan Partners, David Johnson hold 10.4% of SAB Biotherapeutics (NASDAQ: SABS) - Stock Titan
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully - Yahoo Finance
Balyasny Asset Mgmt (SABS) discloses ~9.99% ownership, including warrants - Stock Titan
Chardan Capital Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $14 - Moomoo
SAB Biotherapeutics Q1 2026 Earnings Call Transcript - MarketBeat
SAB Biotherapeutics 1Q Research and Development Expenses $13.4M >SABS - Moomoo
SAB Biotherapeutics Q1 Earnings Call Highlights - sharewise.com
H.C. Wainwright raises SAB Biotherapeutics price target on share count By Investing.com - Investing.com Canada
SAB Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SAB Biotherapeutics (NASDAQ:SABS) Reports Q1 2026 Miss as Clinical Progress and Extended Cash Runway Through 2028 Take Center Stage - ChartMill
Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call - Benzinga
SAB Biotherapeutics raises $95M, expects trial data in 2H 2027 - Investing.com UK
SAB Biotherapeutics raises $95M, expects trial data in 2H 2027 By Investing.com - Investing.com South Africa
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights - The Manila Times
SAB Biotherapeutics 1Q 2026: Net loss $(18.9M), EPS $(0.35) — 10-Q Summary - TradingView
SAB Biotherapeutics (NASDAQ: SABS) posts larger Q1 2026 loss but boosts cash - Stock Titan
TradingKey - TradingKey
SABS Stock Price, Quote & Chart | SAB BIOTHERAPEUTICS INC (NASDAQ:SABS) - ChartMill
SABS shares surge 7.6% despite SAB Biotherapeutics deeper-than-expected quarterly loss; investors bullish on pipeline prospects.EBITDA Margin - newser.com
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET - Investing News Network
SAB Biotherapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):